PharmaEngine, Inc.

Taipei Exchange 4162.TWO

PharmaEngine, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 16.31

PharmaEngine, Inc. Price to Sales Ratio (P/S) is 16.31 on January 14, 2025, a -14.62% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

PharmaEngine, Inc. 52-week high Price to Sales Ratio (P/S) is 20.15 on February 15, 2024, which is 23.60% above the current Price to Sales Ratio (P/S).
PharmaEngine, Inc. 52-week low Price to Sales Ratio (P/S) is 14.11 on August 06, 2024, which is -13.44% below the current Price to Sales Ratio (P/S).
PharmaEngine, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 16.75.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Taipei Exchange: 4162.TWO

PharmaEngine, Inc.

CEO	Mr. Hong-Ren Wang Ph.D.
IPO Date	June 20, 2012
Location	Taiwan
Headquarters	10 Minsheng East Road
Employees	17
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It is developing ONIVYDE, a proprietary liposome encapsulation of irinotecan, a topoisomerase 1 inhibitor for the treatment of metastatic pancreatic cancer; PEP06, which is in Phase I clinical trial for the treatment of cancer; and PEP07, a Chk1 inhibitor, which is in preclinical development stage to accumulate DNA damage in cells, lead to replication catastrophe, and induce cell apoptosis. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

Key trends

Past 5 years